Impax’s Zomig Nasal Spray OK’d as pediatric migraine treatment
HAYWARD, Calif. — Impax Specialty Pharma’s Zomig Nasal Spray has been approved by the Food and Drug Administration for use in children ages 12 and older for the acute treatment of migraine. Parent company Impax Laboratories Inc. said Tuesday that the product is the first nasal-delivered prescription medicine approved for the treatment of acute migraine
